Objectives: To evaluate the fatal impact of COVID-19 on patients with comorbid cardiovascular disease (CVD). Results: Overall, the 28-day mortality of patients with comorbid CVD was 3.25 times of that of patients without comorbid CVD (40.63% vs 12.50%, P=0.011). Clinic symptoms on admission were similar for the two groups. However, patients with comorbid CVD had higher levels of Interleukin-10 (22.22% vs 0%, P=0.034), procalcitonin (22.6% vs 3.13%, P<0.001), high-sensitivity troponin I (20 pg/mL vs 16.05 pg/mL, P=0.019), and lactic dehydrogenase (437 U/L vs 310 U/L, P=0.015). In addition, patients with comorbid CVD experienced a high incidence of acute respiratory distress syndrome (59.38% vs 15.63%, P<0.001), and required more invasive mechanical ventilation (40.63% vs 12.50%, P=0.011). Methylprednisolone was found to improve the survival of patients without comorbid CVD (p = 0.05). Conclusions: Comorbid CVD resulted in a higher mortality rate for COVID-19 patients. Acute respiratory distress syndrome was the primary reason of death for COVID-19 patients with comorbid CVD, followed by acute myocardial infarction. Methods: This retrospective study used propensity score matching to divide 64 COVID-19 patients into two groups with and without comorbid CVD. Clinic symptoms, laboratory features, treatments, and 28-day mortality were compared between the two groups.
【저자키워드】 COVID-19, Corticosteroids, cardiovascular disease, Fatal outcome, 【초록키워드】 interleukin-10, 28-day mortality, procalcitonin, Symptom, Symptoms, Retrospective study, survival, Patient, death, mortality rate, incidence, troponin I, Admission, COVID-19 patients, acute respiratory distress, Invasive mechanical ventilation, propensity score matching, Acute myocardial infarction, distress, COVID-19 patient, Laboratory features, lactic dehydrogenase, CVD, two groups, clinic, syndrome, IMPROVE, evaluate, addition, required, two group, 【제목키워드】 outcome, risk factor, Patient,